Literature DB >> 2211200

Patterns of failure in patients with stage I, grade 3 carcinoma of the endometrium.

K M Greven1, M Randall, J Fanning, M Bahktar, P Duray, A Peters, W J Curran.   

Abstract

Patients with high grade, early stage endometrial carcinoma are reported to have worse survival and local control rates than those with low grade carcinomas. To define failure patterns further in patients with FIGO Stage I, grade 3 endometrial carcinomas, the patients from three institutions who received adjuvant or definitive radiation (RT) were analyzed. Of 119 patients meeting the criteria of Stage I, grade 3 endometrial carcinoma, 57 patients received preoperative radiation, 49 patients received postoperative radiation, and 10 patients received definitive radiation with 5-year actuarial survival rates of 64%, 73%, and 65%, respectively. Three additional patients received both preoperative and postoperative treatment. The overall local control rate was 88% with a median follow-up of 70 months. Of 36 patients who failed, 14 had a component of local failure, and 31 had a component of distant failure. Eighteen of 31 distant failures involved metastatic spread to the abdominal cavity. Recurrence patterns by method of treatment are documented. Patients with high grade tumors do have a propensity for distant metastasis. Clinical investigation into the value of systemic therapy is necessary.

Entities:  

Mesh:

Year:  1990        PMID: 2211200     DOI: 10.1016/0360-3016(90)90477-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.

Authors:  Gary Altwerger; Elena Bonazzoli; Stefania Bellone; Tomomi Egawa-Takata; Gulden Menderes; Francesca Pettinella; Anna Bianchi; Francesco Riccio; Jacqueline Feinberg; Luca Zammataro; Chanhee Han; Ghanshyam Yadav; Katherine Dugan; Ashley Morneault; Jose F Ponte; Natalia Buza; Pei Hui; Serena Wong; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Gloria S Huang; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Mol Cancer Ther       Date:  2018-02-13       Impact factor: 6.261

2.  Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer.

Authors:  Ryan M Tierney; Matthew A Powell; David G Mutch; Randall K Gibb; Janet S Rader; Perry W Grigsby
Journal:  Radiat Med       Date:  2007-11-26

3.  Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer.

Authors:  Jun Zhang; Lanfen An; Xing Zhou; Rui Shi; Hongbo Wang
Journal:  Ann Transl Med       Date:  2021-04

4.  High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome.

Authors:  Gustavo A Viani; Barbara F Patia; Antonio C Pellizzon; Marcel D De Melo; Paulo E Novaes; Ricardo C Fogaroli; Maria A Conte; Joao V Salvajoli
Journal:  Radiat Oncol       Date:  2006-08-03       Impact factor: 3.481

5.  Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

Authors:  Stephanie M de Boer; Melanie E Powell; Linda Mileshkin; Dionyssios Katsaros; Paul Bessette; Christine Haie-Meder; Petronella B Ottevanger; Jonathan A Ledermann; Pearly Khaw; Alessandro Colombo; Anthony Fyles; Marie-Helene Baron; Ina M Jürgenliemk-Schulz; Henry C Kitchener; Hans W Nijman; Godfrey Wilson; Susan Brooks; Silvestro Carinelli; Diane Provencher; Chantal Hanzen; Ludy C H W Lutgens; Vincent T H B M Smit; Naveena Singh; Viet Do; Romerai D'Amico; Remi A Nout; Amanda Feeney; Karen W Verhoeven-Adema; Hein Putter; Carien L Creutzberg
Journal:  Lancet Oncol       Date:  2018-02-12       Impact factor: 41.316

6.  Long-Term Follow-Up Results of Adjuvant Intensity-Modulated Radiotherapy with Concurrent Paclitaxel and Cisplatin in High-Risk Endometrial Cancer Patients.

Authors:  Pei Shu; Xin Wang; Ganlu Ouyang; Jitao Zhou; Yaqin Zhao; Fang Wang; Zhiping Li; Yali Shen
Journal:  J Oncol       Date:  2022-10-11       Impact factor: 4.501

7.  Risk factors for recurrence amongst high intermediate risk patients with endometrioid adenocarcinoma.

Authors:  Agnes Y Bahng; Christina Chu; Paul Wileyto; Stephen Rubin; Lilie L Lin
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

8.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

Authors:  Nicoletta Colombo; Carien Creutzberg; Frederic Amant; Tjalling Bosse; Antonio González-Martín; Jonathan Ledermann; Christian Marth; Remi Nout; Denis Querleu; Mansoor Raza Mirza; Cristiana Sessa
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.